Search for: "Boehringer Ingelheim, Inc."
Results 41 - 60
of 155
Sort by Relevance
|
Sort by Date
3 Jun 2014, 4:41 pm
That same year, Boehringer Ingelheim Pharmaceuticals, Inc. made $1.5 billion in sales of Pradaxa. [read post]
3 Apr 2014, 5:00 am
Jan. 30, 2014) (“Actos”); In re Ethicon, Inc. [read post]
13 Feb 2014, 6:00 am
District Court Judge David Herndon from the Southern District of Illinois imposed close to $1 million in punitive damages on defendants Boehringer Ingelheim International GMBH (“BII”) and Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
28 Jan 2014, 11:53 am
In re Petition of Boehringer Ingelheim Pharmaceuticals, Inc., and Boehringer Ingelheim Int’l. [read post]
25 Jan 2014, 9:43 am
In re Petition of Boehringer Ingelheim Pharmaceuticals, Inc., No. 13-3898 (7th Cir. [read post]
15 Jan 2014, 5:43 am
Herndon of the Southern District of Illinois has ordered that Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
24 Dec 2013, 5:49 am
” Boehringer Ingelheim Vetmedica, Inc. v. [read post]
1 Aug 2013, 9:29 am
The generic and brand names of the drugs in this family include: • Exenatide (Byetta & Bydureon) marketed by Bristol Myers-Squibb and Amylin Pharmaceuticals, Inc. [read post]
28 Jul 2013, 9:29 am
Some of the other diabetes drugs being investigated include Bydureon and Onglyza, sold by Bristol-Myers Squibb; AstraZeneca and Victoza from Novo Nordisk; Tradjenta from Eli Lilly and Boehringer Ingelheim; and Nesina from Takeda. [read post]
2 May 2013, 10:30 am
On March 26, 2013, Plaintiff Lisa Mulhall filed a claim in the Illinois Southern District Court against the manufacturers of Pradaxa, Boehringer Ingelheim Pharmaceuticals, Inc. and Boehringer Ingelheim International GmbH, for causing her mother’s death. [read post]
31 Jan 2013, 12:57 pm
The plaintiffs brought a product liability claim against Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
23 Jan 2013, 4:16 pm
” Boehringer Ingelheim Vetmedica, Inc. v. [read post]
26 Dec 2012, 1:35 pm
A Look At The Events And The Evidence Leading Up To This Latest FDA Action Concerning The Safety Of Pradaxa (Posted by Tom Lamb at DrugInjuryWatch.com) We set the stage with this December 19, 2012 drug company press release, "Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
20 Nov 2012, 8:32 am
This settlement was with pharmaceutical giant Boehrigner Ingelheim Pharmaceuticals Inc. [read post]
9 Nov 2012, 2:15 pm
" November 7, 2012: "Interim Results from RELY-ABLE®, the RE-LY® Extension Study, Provide Additional Clinical Evidence for the Safety of Pradaxa® (dabigatran etexilate mesylate)" (Drug company Press Release) @EXCERPT: Boehringer Ingelheim Pharmaceuticals, Inc. today announced interim results from the RELY-ABLE® trial, a long-term extension of the RE-LY® study. [read post]
2 Nov 2012, 11:58 am
Boehringer Ingelheim Pharmaceuticals, Inc., 2009 WL 702007, at *3-4 (D. [read post]
29 Oct 2012, 11:40 am
Boehringer Ingelheim Pharmaceuticals, Inc. [read post]
28 Oct 2012, 6:37 pm
Boehringer Ingelheim Pharmaceuticals Inc., a Germany-based pharmaceutical company that markets and sells drugs in the United States, has recently agreed to settle claims that it illegally promoted four of its best-selling drugs for $95 million. [read post]
26 Oct 2012, 4:31 am
According to DOJ’s press release: Connecticut-based Boehringer Ingelheim Pharmaceuticals Inc. has agreed to pay $95 million to resolve allegations relating to the improper promotion of the stroke-prevention drug Aggrenox, the chronic obstructive pulmonary disease (COPD) drugs Atrovent and Combivent, and the hypertension drug Micardis, the Justice Department announced today. [read post]
11 Oct 2012, 3:52 pm
Boehringer Ingelheim Vetmedica, Inc., C.A. [read post]
